Moderately hypofractionated radiotherapy, both isodose and dose-escalated, led to progression-free survival outcomes similar to that achieved with conventionally fractionated radiotherapy in patients ...

The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over ...

The findings, published in JAMA Network Open, were reported by Cristian Udovicich of the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues. The investigators ...

The 2 groups--those receiving ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy--had similar overall survival, which was 81% and 79%, respectively, at 10 years.

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

Evaluation of post radiotherapy PSA as a prognostic and predictive biomarker in high risk prostate cancer: A secondary analysis of RTOG 0521. Results of AFU-GETUG-20: A randomised phase 3 trial of ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

According to data from two phase III trials presented at this year's American Society of Clinical Oncology Genitourinary Cancers Symposium, patients with high-risk prostate cancer had a significantly ...

A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...

NEW ORLEANS - Ochsner MD Anderson Cancer Center will be the first in the South to offer Biology-Guided Radiotherapy, joining ...

Men with prostate cancer are being denied NHS access to a treatment used by Lord Cameron, a senior doctor has revealed.